公开(公告)号：US12091442B2

公开(公告)日：2024-09-17

申请号：US17824294

申请日：2022-05-25

Applicant: CytomX Therapeutics, Inc.

Inventor： Sayantan Mitra ,  Nicole G. Lapuyade ,  Hikmat Haizar Assi ,  Madan M. Paidhungat ,  Dylan L. Daniel ,  Erwan Le Scolan ,  Walter A. Bogdanoff ,  Na Cai ,  Hsin Wang

IPC: C07K14/56

CPC classification number: C07K14/56 ,  C07K2319/02 ,  C07K2319/30

Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

公开(公告)号：US12084497B2

公开(公告)日：2024-09-10

申请号：US17266250

申请日：2019-08-08

Applicant: Orionis Biosciences, Inc. ,  Orionis Biosciences BV

Inventor： Nikolai Kley ,  Jan Tavernier

IPC: C07K16/28 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/56 ,  C07K14/565

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K14/56 ,  C07K14/565 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/30

Abstract: The present invention relates, in part, to agents that bind SIRP1α and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the SIRP1α targeting moiety and their use in the treatment of various diseases.

公开(公告)号：US12009079B2

公开(公告)日：2024-06-11

申请号：US16663527

申请日：2019-10-25

Applicant: Janssen Biotech, Inc.

Inventor： Matteo Cesaroni ,  Marc Chevrier ,  Jarrat Jordan ,  Jessica Schreiter

IPC: C07K14/56 ,  C12Q1/6809 ,  G16H20/10 ,  G16H50/30

CPC classification number: G16H20/10 ,  C07K14/56 ,  C12Q1/6809 ,  G16H50/30 ,  C07K2317/565 ,  C12Q2539/00 ,  C12Q2545/114

Abstract: Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.

公开(公告)号：US11872250B2

公开(公告)日：2024-01-16

申请号：US17150574

申请日：2021-01-15

Applicant: Rutgers, The State University of New Jersey

Inventor： Yufang Shi ,  Guangwen Ren ,  Liying Zhang

IPC: A61K35/28 ,  A61K38/21 ,  A61K38/20 ,  A61K38/19 ,  A61K38/18 ,  A61P37/04 ,  C12N5/00 ,  C12N5/0775 ,  C12N5/074 ,  A61P37/06 ,  C07K14/50 ,  C07K14/525 ,  C07K14/54 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K14/52 ,  C07K14/545 ,  A61K35/12 ,  A61K45/06 ,  A61P37/02 ,  C07K14/495

CPC classification number: A61K35/28 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/191 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61P37/04 ,  A61P37/06 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0662 ,  C12N5/0663 ,  C12N5/0665 ,  A61K45/06 ,  A61K2035/122 ,  A61P37/02 ,  C07K14/495 ,  C07K14/50 ,  C07K14/52 ,  C07K14/525 ,  C07K14/545 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C12N2500/05 ,  C12N2501/10 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2317 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2502/1114 ,  A61K35/28 ,  A61K2300/00 ,  A61K38/191 ,  A61K2300/00 ,  A61K38/2006 ,  A61K2300/00 ,  A61K38/217 ,  A61K2300/00

Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

公开(公告)号：US20230295304A1

公开(公告)日：2023-09-21

申请号：US17938109

申请日：2022-10-05

Applicant: Orionis Biosciences Inc. ,  Orionis Biosciences BV

Inventor： Nikolai KLEY ,  Jan TAVERNIER ,  Lennart ZABEAU ,  Erik DEPLA

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/56 ,  C07K14/565

CPC classification number: C07K16/2827 ,  A61P35/00 ,  C07K14/56 ,  C07K14/565 ,  A61K2039/505

Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.

公开(公告)号：US20230242577A1

公开(公告)日：2023-08-03

申请号：US17990515

申请日：2022-11-18

Applicant: UBIPROTEIN, CORP.

Inventor： Kyunggon Kim ,  Kwang-Hyun Baek ,  Sung-Ryul Bae ,  Myung-Sun Kim ,  Hyeonmi Kim ,  Yeeun Yoo ,  Lan Li ,  Jung-Hyun Park ,  Jin-Ok Kim

IPC: C07K1/107 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00

CPC classification number: C07K1/1075 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/5759 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00 ,  A61K38/00

Abstract: The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.

公开(公告)号：US20230242575A1

公开(公告)日：2023-08-03

申请号：US17990497

申请日：2022-11-18

Applicant: UBIPROTEIN, CORP.

Inventor： Kyunggon Kim ,  Kwang-Hyun Baek ,  Sung-Ryul Bae ,  Myung-Sun Kim ,  Hyeonmi Kim ,  Yeeun Yoo ,  Lan Li ,  Jung-Hyun Park ,  Jin-Ok Kim

IPC: C07K1/107 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00

CPC classification number: C07K1/1075 ,  C07K14/49 ,  C07K14/50 ,  C07K14/505 ,  C07K14/51 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/575 ,  C07K14/5759 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K16/00 ,  A61K38/00

Abstract: The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.

公开(公告)号：US20230227847A1

公开(公告)日：2023-07-20

申请号：US17998587

申请日：2021-04-07

Applicant: UNIVERSITÄT ZÜRICH

Inventor： Ulrich SILER ,  Janine REICHENBACH ,  Martina NUBIE

IPC: C12N15/86 ,  C07K14/54 ,  C07K14/57 ,  C07K14/535 ,  C07K14/55 ,  C07K14/56 ,  A61P25/28

CPC classification number: C12N15/86 ,  C07K14/5434 ,  C07K14/57 ,  C07K14/535 ,  C07K14/55 ,  C07K14/5443 ,  C07K14/56 ,  A61P25/28

Abstract: The present invention provides novel viral vectors for use in human therapy, particularly for use in in the treatment of a disease or disorder which has its origin in the brain or is brain based, particularly a PGRN-associated neurodegenerative disease or disorder including frontotemporal degenerative disease or disorder such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The invention also provides viral vectors for use in the treatment of brain tumors, particularly brain tumors selected from the group consisting of glioblastoma, glioma, ganglioneuroblastoma, astrocytoma, oligodendroglioma, PNET (primitive neuroectodermal), medulloblastoma, CNS lymphoma, and neuroblastoma, or any other CNS tumor and further in the treatment of brain metastasis, originating from any forms of breast, lung, colon, testicular, renal carcinomas and melanoma, or any other solid tumor, and any hematologic tumor, comprising all forms of leukemia and lymphomas. Further, the viral vectors may be used in the treatment of autoimmune diseases, inflammatory diseases and/or allergic diseases.

公开(公告)号：US20190233492A1

公开(公告)日：2019-08-01

申请号：US16376216

申请日：2019-04-05

Applicant: President and Fellows of Harvard College ,  Dana-Farber Cancer Institute, Inc.

Inventor： Jeffrey Charles Way ,  Avram Lev Robinson-Mosher ,  Thomas M. Roberts ,  Jean Zhao

IPC: C07K14/56 ,  C07K16/32 ,  C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K38/21

CPC classification number: C07K14/56 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/01

Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer

公开(公告)号：US20190192673A1

公开(公告)日：2019-06-27

申请号：US16311540

申请日：2017-06-16

Applicant: ELANCO US INC. ,  AMBRX, INC.

Inventor： Peter Connor CANNING ,  Nickolas KNUDSEN ,  Lillian SKIDMORE

IPC: A61K47/60 ,  C07K14/56 ,  A61K47/12 ,  A61K47/02 ,  A61K47/10 ,  A61K9/00 ,  A61P31/14

CPC classification number: A61K47/60 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61P31/14 ,  C07K14/56

Abstract: Disclosed herein are porcine interferon alpha variants (pINF-α) comprising a synthetic amino acid at select locations in pINF-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.